Key result
Sub-Saharan Africa features in only ~10% of trials informing ESC guidelines for HF and ACS.
Why the study?
There is a growing burden of ACS and HF in sub-Saharan Africa, but the representation of populations from sub-Saharan Africa in ESC international guidelines remains unclear.
Systematic Review (n=462)
Sub-Saharan African countries are markedly underrepresented in the RCTs that inform ESC ACS and HF guidelines, potentially limiting the generalizability of these guidelines to SSA populations.
Answers are grounded in this paper and cite their sources.
May limit applicability of ESC HF/ACS guidelines in Sub-Saharan Africa; challenges adequacy of current RCT evidence base for global recommendations.
Background: There is a growing burden of acute coronary syndrome (ACS) and heart failure (HF) in sub-Saharan Africa (SSA), yet outcomes remain poor compared to high-income countries. The European Society of Cardiology (ESC) international guidelines are pivotal to the delivery of evidence-based care; however, their representation of populations from SSA remains unclear. Objectives: The purpose of the study was to evaluate the representation of populations from SSA in randomized controlled trials (RCTs) that inform ESC ACS and HF guidelines. Methods: We systematically analyzed pharmacotherapeutic RCTs contributing to the 2021 ESC HF and 2023 ACS guidelines, extracting data from ClinicalTrials.gov. We assessed the proportion of RCTs that included contributions from countries in each World Bank income group, focusing on the involvement of SSA countries and examining temporal trends. Results: for trend = 0.003), then declined to 11.3% in the following decade. Conclusions: There is a marked underrepresentation of SSA countries in ACS and HF pharmacotherapy RCTs. South Africa is the sole contributor from the region, which may affect applicability and generalizability of global guidelines to populations in SSA.
No takes yet. Share an insight, caveat, or question.
Hudson et al. (2024) conducted a systematic review in Acute Coronary Syndrome and Heart Failure (n=462). Pharmacotherapy randomized controlled trials was evaluated on Proportion of studies that included a trial site in Sub-Saharan Africa. Among 462 pharmacotherapy randomized controlled trials informing European Society of Cardiology guidelines for heart failure and acute coronary syndromes, only 9.7% included a site in Sub-Saharan Africa.
Synapse has enriched 10 related papers. Consider them for comparative context: